Fecal gut microbiota and amino acids as noninvasive diagnostic biomarkers of Pediatric inflammatory bowel disease.

IF 12.2 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Gut Microbes Pub Date : 2025-12-01 Epub Date: 2025-06-12 DOI:10.1080/19490976.2025.2517828

Eva Vermeer, Jasmijn Z Jagt, Eline M Lap, Eduard A Struys, Andries E Budding, Nanda M Verhoeven-Duif, Marjolein Bosma, Johan E van Limbergen, Bart G P Koot, Robert de Jonge, Marc A Benninga, Animesh Acharjee, Nanne K H de Boer, Tim G J de Meij

{"title":"Fecal gut microbiota and amino acids as noninvasive diagnostic biomarkers of Pediatric inflammatory bowel disease.","authors":"Eva Vermeer, Jasmijn Z Jagt, Eline M Lap, Eduard A Struys, Andries E Budding, Nanda M Verhoeven-Duif, Marjolein Bosma, Johan E van Limbergen, Bart G P Koot, Robert de Jonge, Marc A Benninga, Animesh Acharjee, Nanne K H de Boer, Tim G J de Meij","doi":"10.1080/19490976.2025.2517828","DOIUrl":null,"url":null,"abstract":"Background and aims: Fecal calprotectin (FCP) has limited specificity as diagnostic biomarker of pediatric inflammatory bowel disease (IBD), leading to unnecessary invasive endoscopies. This study aimed to develop and validate a fecal microbiota and amino acid (AA)-based diagnostic model.Methods: Fecal samples from a discovery cohort (de novo IBD and healthy controls [HC]) were used to develop the diagnostic model. This model was applied in a validation cohort (de novo IBD and controls with gastrointestinal symptoms [CGI]). Microbiota and AAs were analyzed using interspace profiling and liquid chromatography-mass spectrometry techniques, respectively. Machine learning techniques were used to build the diagnostic model.Results: In the discovery cohort (58 IBD, 59 hC), two microbial species (Escherichia coli and Alistipes finegoldii) and four AAs (leucine, ornithine, taurine, and alpha-aminoadipic acid [AAD]) combined allowed for discrimination between both subgroups (AUC 0.94, 95% CI [0.89, 0.98]). In the validation cohort (43 IBD, 38 CGI), this panel of six markers could differentiate patients with IBD from CGI with an AUC of 0.84, 95% CI [0.67, 0.95]). Leucine showed the best diagnostic performance (AUC 0.89, 95% CI [0.81, 0.95]).Conclusions: Leucine might serve as adjuvant noninvasive biomarker in the diagnostic work-up of pediatric IBD. Future research should investigate whether the combination of leucine with FCP could improve specificity and may help tailor the course of diagnostics.","PeriodicalId":12909,"journal":{"name":"Gut Microbes","volume":"17 1","pages":"2517828"},"PeriodicalIF":12.2000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12164387/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut Microbes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/19490976.2025.2517828","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and aims: Fecal calprotectin (FCP) has limited specificity as diagnostic biomarker of pediatric inflammatory bowel disease (IBD), leading to unnecessary invasive endoscopies. This study aimed to develop and validate a fecal microbiota and amino acid (AA)-based diagnostic model.

Methods: Fecal samples from a discovery cohort (de novo IBD and healthy controls [HC]) were used to develop the diagnostic model. This model was applied in a validation cohort (de novo IBD and controls with gastrointestinal symptoms [CGI]). Microbiota and AAs were analyzed using interspace profiling and liquid chromatography-mass spectrometry techniques, respectively. Machine learning techniques were used to build the diagnostic model.

Results: In the discovery cohort (58 IBD, 59 hC), two microbial species (Escherichia coli and Alistipes finegoldii) and four AAs (leucine, ornithine, taurine, and alpha-aminoadipic acid [AAD]) combined allowed for discrimination between both subgroups (AUC 0.94, 95% CI [0.89, 0.98]). In the validation cohort (43 IBD, 38 CGI), this panel of six markers could differentiate patients with IBD from CGI with an AUC of 0.84, 95% CI [0.67, 0.95]). Leucine showed the best diagnostic performance (AUC 0.89, 95% CI [0.81, 0.95]).

Conclusions: Leucine might serve as adjuvant noninvasive biomarker in the diagnostic work-up of pediatric IBD. Future research should investigate whether the combination of leucine with FCP could improve specificity and may help tailor the course of diagnostics.

查看原文本刊更多论文

粪便肠道菌群和氨基酸作为儿童炎症性肠病的无创诊断生物标志物。

背景和目的：粪便钙保护蛋白（FCP）作为儿童炎症性肠病（IBD）的诊断生物标志物特异性有限，导致不必要的侵入性内窥镜检查。本研究旨在建立并验证基于粪便微生物群和氨基酸（AA）的诊断模型。方法：使用发现队列（新发IBD和健康对照[HC]）的粪便样本建立诊断模型。该模型应用于一个验证队列（新发IBD患者和有胃肠道症状的对照组[CGI]）。微生物群和原子吸收光谱分别采用空间谱法和液相色谱-质谱法进行分析。采用机器学习技术建立诊断模型。结果：在发现队列（58例IBD， 59例hC）中，两种微生物（大肠杆菌和细谷阿里氏杆菌）和四种氨基酸（亮氨酸、鸟氨酸、牛磺酸和α -氨基己二酸[AAD]）可以在两个亚组之间进行区分（AUC 0.94, 95% CI[0.89, 0.98]）。在验证队列（43名IBD， 38名CGI）中，这6个标记可以区分IBD和CGI患者，AUC为0.84,95% CI[0.67, 0.95])。亮氨酸的诊断效果最好（AUC 0.89, 95% CI[0.81, 0.95]）。结论：亮氨酸可作为儿童IBD诊断的辅助无创生物标志物。未来的研究应探讨亮氨酸与FCP联合使用是否可以提高特异性，并可能有助于调整诊断过程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gut Microbes Medicine-Microbiology (medical)

CiteScore

18.20

自引率

3.30%

发文量

196

审稿时长

10 weeks

期刊介绍： The intestinal microbiota plays a crucial role in human physiology, influencing various aspects of health and disease such as nutrition, obesity, brain function, allergic responses, immunity, inflammatory bowel disease, irritable bowel syndrome, cancer development, cardiac disease, liver disease, and more. Gut Microbes serves as a platform for showcasing and discussing state-of-the-art research related to the microorganisms present in the intestine. The journal emphasizes mechanistic and cause-and-effect studies. Additionally, it has a counterpart, Gut Microbes Reports, which places a greater focus on emerging topics and comparative and incremental studies.